RS50896B - Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka - Google Patents

Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka

Info

Publication number
RS50896B
RS50896B YUP-214/04A YUP21404A RS50896B RS 50896 B RS50896 B RS 50896B YU P21404 A YUP21404 A YU P21404A RS 50896 B RS50896 B RS 50896B
Authority
RS
Serbia
Prior art keywords
alkoxy
optionally substituted
aryl
alkyl
group
Prior art date
Application number
YUP-214/04A
Other languages
English (en)
Inventor
François CLERC
François HAMY
Isabelle Depaty
Odile Angouillant-Boniface
Stéphanie Deprets
Chantal Carrez
Manfred Roesner
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Priority to MEP-168/08A priority Critical patent/MEP16808A/xx
Publication of YU21404A publication Critical patent/YU21404A/sh
Publication of RS50896B publication Critical patent/RS50896B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • C07D235/32Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
YUP-214/04A 2001-09-26 2002-09-26 Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka RS50896B (sr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-168/08A MEP16808A (en) 2001-09-26 2002-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01402460A EP1298125A1 (en) 2001-09-26 2001-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer

Publications (2)

Publication Number Publication Date
YU21404A YU21404A (sh) 2006-08-17
RS50896B true RS50896B (sr) 2010-08-31

Family

ID=8182891

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-214/04A RS50896B (sr) 2001-09-26 2002-09-26 Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka

Country Status (35)

Country Link
US (1) US7041668B2 (sr)
EP (2) EP1298125A1 (sr)
JP (1) JP4510450B2 (sr)
KR (1) KR100891439B1 (sr)
CN (1) CN100346786C (sr)
AR (1) AR037096A1 (sr)
AT (1) ATE386517T1 (sr)
AU (1) AU2002337151B2 (sr)
BR (1) BR0212856A (sr)
CA (1) CA2461622C (sr)
CO (1) CO5570675A2 (sr)
CY (1) CY1107953T1 (sr)
DE (1) DE60225159T2 (sr)
DK (1) DK1432417T3 (sr)
EA (1) EA006802B1 (sr)
ES (1) ES2301682T3 (sr)
GT (1) GT200200190A (sr)
HK (1) HK1068551A1 (sr)
HR (1) HRPK20040293B3 (sr)
HU (1) HUP0401756A3 (sr)
IL (1) IL161059A0 (sr)
ME (1) MEP16808A (sr)
MX (1) MXPA04002042A (sr)
MY (1) MY135339A (sr)
NO (1) NO327008B1 (sr)
NZ (1) NZ531246A (sr)
PA (1) PA8555501A1 (sr)
PE (1) PE20030427A1 (sr)
PL (1) PL369527A1 (sr)
PT (1) PT1432417E (sr)
RS (1) RS50896B (sr)
SI (1) SI1432417T1 (sr)
UY (1) UY27452A1 (sr)
WO (1) WO2003028721A2 (sr)
ZA (1) ZA200401887B (sr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
CA2542064A1 (en) * 2003-10-24 2005-05-06 Exelixis, Inc. Tao kinase modulators and methods of use
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
AU2005326962A1 (en) 2004-12-22 2006-08-17 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
CN101300251B (zh) * 2005-09-06 2011-08-03 史密丝克莱恩比彻姆公司 作为plk抑制剂的苯并咪唑噻吩化合物
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
ES2533463T3 (es) 2006-10-12 2015-04-10 Bhi Limited Partnership Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
PL2722046T3 (pl) * 2007-10-12 2017-06-30 Abbvie Ireland Unlimited Company Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
FR2941950B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011091152A1 (en) * 2010-01-22 2011-07-28 Pablo Gastaminza Inhibitors of hepatitis c virus infection
WO2017035340A1 (en) 2015-08-25 2017-03-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2441201C2 (de) * 1974-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung
DE2541752A1 (de) 1975-09-19 1977-03-24 Hoechst Ag Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
DK1432417T3 (da) 2008-06-16
US7041668B2 (en) 2006-05-09
NO20041214L (no) 2004-06-24
CA2461622C (en) 2008-12-02
ES2301682T3 (es) 2008-07-01
AU2002337151B2 (en) 2007-04-26
EA006802B1 (ru) 2006-04-28
JP4510450B2 (ja) 2010-07-21
PL369527A1 (en) 2005-05-02
MY135339A (en) 2008-03-31
CY1107953T1 (el) 2013-09-04
EP1298125A1 (en) 2003-04-02
CN100346786C (zh) 2007-11-07
GT200200190A (es) 2003-11-11
CO5570675A2 (es) 2005-10-31
IL161059A0 (en) 2004-08-31
HRPK20040293B3 (en) 2007-06-30
NZ531246A (en) 2006-06-30
PA8555501A1 (es) 2003-06-30
EP1432417A2 (en) 2004-06-30
SI1432417T1 (sl) 2008-08-31
AR037096A1 (es) 2004-10-20
MXPA04002042A (es) 2004-06-07
HK1068551A1 (en) 2005-04-29
CA2461622A1 (en) 2003-04-10
EA200400475A1 (ru) 2004-08-26
PE20030427A1 (es) 2003-06-20
HUP0401756A2 (hu) 2005-01-28
ZA200401887B (en) 2005-05-31
DE60225159T2 (de) 2009-02-19
KR20040048904A (ko) 2004-06-10
NO327008B1 (no) 2009-04-06
PT1432417E (pt) 2008-05-23
WO2003028721A2 (en) 2003-04-10
ATE386517T1 (de) 2008-03-15
EP1432417B1 (en) 2008-02-20
JP2005504112A (ja) 2005-02-10
HRP20040293A2 (en) 2005-06-30
WO2003028721A3 (en) 2003-12-11
CN1558761A (zh) 2004-12-29
US20050014811A1 (en) 2005-01-20
HUP0401756A3 (en) 2005-06-28
UY27452A1 (es) 2003-02-28
YU21404A (sh) 2006-08-17
DE60225159D1 (de) 2008-04-03
MEP16808A (en) 2010-06-10
BR0212856A (pt) 2004-09-14
KR100891439B1 (ko) 2009-04-03

Similar Documents

Publication Publication Date Title
RS50896B (sr) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
RS53668B1 (sr) Derivati hidroksibenzamida i njihova primena kao inhibitora hsp90
TW200738682A (en) Isoquinoline derivatives
PE20040893A1 (es) DERIVADOS DE INDOL O DERIVADOS DE BENCIMIDAZOL PARA MODULAR IkB QUINASA
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
RS51471B (sr) Derivati bifeniloksisirćetne kiseline za tretman bolesti dišnog trakta
RS54260B1 (sr) Derivati aminodihidrotiazina kao bace inhibitori za tretman alzheimerove bolesti
ATE463483T1 (de) 6-substituierte isochinolinderivate als rock-1- inhibitoren
RS51047B (sr) Derivati 4-tetrazolil-4-fenilpiperidina za lečenje bola
RS53226B (sr) Novi derivati fenilimidazola kao inhibitori enzima pde10a
RS53500B1 (sr) Supstituisana jedinjenja n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-karboksamida kao cfms inhibitori
RS53379B (sr) Derivati n-fenil-2-pirimidin-amina i postupak za njihovo pripremanje
RS53246B (sr) Derivati imidazola kao inhibitori kazein kinaze
RS52978B (sr) Fuzionisan amino piridin kao hsp90 inhibitori
RS52562B (sr) (3-aril-piperazin-1-il) derivati 6,7-dialkoksikvinazolina, 6,7- dialkoksiftalazina i 6,7-dialkoksiizokvinolina
RS54070B1 (sr) SUPSTITUISANA N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a]PIRIDIN-3-KARBOKSAMIDNA JEDINJENJA KAO INHIBITORI TIPA III RECEPTORA TIROZIN KINAZE
RS53019B (sr) Derivati adamantil diamida i njihova upotreba
DE60014393D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
EA201170237A1 (ru) Производные карбаматов алкилтиазолов, их получение и их применение в терапии
RS54183B1 (sr) Derivati pirazola
ME00108B (me) DE RIVATI DIOKSAN-2-ALKILKARBAMATA, POSTUPAK ZA NJIHOVO DOBIJANJ E l PRIMENA ISTIH U TERAPEUTICIMA
AR060438A1 (es) 2-(piridin-2-il) - pirimidinas como fungicidas.
RS51692B (sr) Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze
EA201171385A1 (ru) Производные циклопента[с]пирролилалкилкарбаматов 5-членных гетероциклов, способ их получения и применение их в терапии
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат